2025 first_quarter Filing
Q1Lobbying Activities
Patient access and maintain six protected classes for depressions and schizophrenia under Medicare Part D; Inflation Reduction Act of 2022 implementation, Part D redesign phase-in for small companies;
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026; PDUFA implementation and efficiency improvements at the FDA; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act;